hrp0097p1-42 | Diabetes and Insulin | ESPE2023

Type 1 diabetes in the covid pandemic: what changed?

Diogo Rui , Rua Inês , Cardoso Rita , Dinis Isabel , Mirante Alice , Serra-Caetano Joana

Introduction: The COVID-19 pandemic adversely impacted general access to healthcare. An association between SARS-CoV-2 infection and new-onset type 1 Diabetes (T1D), a more severe disease at diagnosis and a worsening diabetes control have been described.Aim: To evaluate COVID-19 pandemic’s impact in incidence and presentation of T1D on paediatric patients.Material and Methods:</strong...

hrp0086p2-p877 | Syndromes: Mechanisms and Management P2 | ESPE2016

Pituitary Gigantism and Central Precocious Puberty Presenting with Prognathism in a Pediatric Patient

Minutti Carla , Idrovo Alexandra

Case Report: A 13-year old male presented to a dental office for evaluation of prognathism. After evaluation, his dentist referred him to pediatric endocrinology. He had no significant past medical history. He denied any signs or symptoms associated with any hormonal deficit or excess, as well as headaches or visual disturbances. Denied excessive growth of hands or feet. Parents reported that he had been having pubic and axillary hair, mild acne, and significant growth for the...

hrp0084p3-944 | GH &amp; IGF | ESPE2015

The Impact of GH Therapy in Noonan Syndrome Children with Identified Mutations in RAS/MAPK Pathway

Malaquias Alexsandra , Moraes Michelle , Funari Mariana , Pereira Alexandre , Bertola Debora , Jorge Alexander

Objective: To evaluate the response to recombinant human GH (rhGH) treatment in NS children with short stature and previously identified mutations in the RAS/MAPK pathway genes.Methods: 23 patients with NS (17 males; 19 PTPN11, 3 RAF1 e 1 SHOC2) were daily treated with rhGH (mean rhGH dose of 47 μg/kg per day). The main outcome measures were 1st year growth velocity, change in height SDS (Noonan syndrome specifi...

hrp0089p1-p068 | Diabetes &amp; Insulin P1 | ESPE2018

Impact on Final Height of Functional Insulin-Therapy in Type 1 Diabetes Mellitus Pediatric Patients – Experience from a Portuguese Pediatric Endocrinology Unit

Serra-Caetano Joana , Dias Ana Lopes , Ferraz Ana , Lages Adriana , Miranda Patricia , Cardoso Rita , Dinis Isabel , Mirante Alice

Introduction: Type 1 diabetes mellitus (1DM) has well known long term vascular and neuropathic complications. It has also been described a positive effect of good glycemic control on physical growth and pubertal development, achieved with improvement of insulin-therapy.Aim: To evaluate the effect of functional insulin-therapy on final height in children with type 1 diabetes mellitus.Methods: Retrospective analysis of a cohort of po...

hrp0089p3-p381 | Thyroid P3 | ESPE2018

Growth Catch-up on Acquired Hypothyroidism Presenting with Growth Delay

Serra-Caetano Joana , Miranda Patricia , Ferraz Ana , Dias Ana Lopes , Lages Adriana , Cardoso Rita , Dinis Isabel , Mirante Alice

Introduction: Hypothyroidism is a frequent endocrinopathy in pediatric age. The most common manifestation in children is growth delay with decreased height velocity. Symptoms can be insidious and, if not identified ant treated, result in short stature.Aim: To evaluate stature catch-up after replacement therapy in children with primary acquired hypothyroidism.Methods: Retrospective study of all children with primary acquired hypothy...

hrp0082p3-d1-709 | Diabetes | ESPE2014

Continuous Subcutaneous Insulin Infusion Therapy in Preschool Children with Type 1 Diabetes Mellitus

Moinho Rita , Martins Dora , Almeida Angela , Maia Estefania , Batista Nanci , Aveiro Lina , Capitao Rita , Cardoso Rita , Dinis Isabel , Mirante Alice

Background: A good metabolic control in preschool children with type 1 diabetes (DM1) is particularly challenging, being easier and safer with continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI).Objective and hypotheses: Evaluate and compare metabolic control of preschool children with DM1, before and 9 months after CSII therapy.Method: Analytical retrospective study of children under the a...

hrp0082p3-d3-755 | Diabetes (4) | ESPE2014

Multiple Daily Injections Since the Diagnosis of Type 1 Diabetes Mellitus in Children and Adolescents: Assessment of 3 Years

Cardoso Rita , Martins Dora , Batista Nanci , Aveiro Lina , Capitao Rita , Ribeiro Helena , Freitas Filomena , Simao Luisa , Dinis Isabel , Mirante Alice

Background: Functional insulin therapy allows precise insulin adjustments to achieve normoglycaemia.Objective and hypotheses: To assess metabolic control (A1c) and lipid profile in children and adolescents with DM1 in a 3-year period under multiple daily injections (MDI) since the diagnosis.Method: Retrospective analysis of children and adolescents under functional insulin therapy since the diagnosis of DM1. The variables studied w...

hrp0084p3-1036 | Growth | ESPE2015

Impact of GH Treatment in Children Final Height and Weight Status

Guelho Daniela , Almiro Maria Miguel , Dantas Rosa , Paiva Isabel , Bastos Margarida , Serra-Caetano Joana , Cardoso Rita , Dinis Isabel , Mirante Alice

Background: GH revolutionised treatment of children with GH deficiency, conditioning an improvement in height outcome but also an increase of lean body mass and reduction of fat mass.Objective and hypotheses: The authors aimed to evaluate the growth and weight response in children with GH deficiency and identify potential factors affecting the outcome of these patients.Method: The growth and weight data of 58 children (33 boys and ...

hrp0084p3-1149 | Puberty | ESPE2015

Idiopathic Central Precocious Puberty – Treatment Criteria

Serra-Caetano Joana , Coutinho Rita , Almiro Maria Miguel , Guelho Daniela , Dantas Rosa , Cardoso Rita , Dinis Isabel , Mirante Alice

Background: Central precocious puberty is due to premature activation of the hypothalamo–pituitary–ovarian axis. In girls it is idiopathic in up to 95%. Children with clinical rapid progression are treated with prolonged activity GnRH agonist.Objective and hypotheses: Characterise cases of idiopathic central precocious puberty (ICPP) followed at our hospital comparing the group treated with GnRH agonist (group A) with the group not treated (gro...

hrp0089fc15.4 | Growth and Syndromes | ESPE2018

The Metabolic Profile Associated with RASopathies

Noronha Renata , Homma Thais , Moraes Michelle , Albuquerque Edoarda , Funari Mariana , Pereira Alexandre , Villares Sandra , Bertola Debora , Jorge Alexander , Malaquias Alexsandra

Background: Noonan syndrome (NS) is a frequent autosomal dominant disorder characterized by facial dysmorphisms, heart defects, short stature and learning disabilities. It is caused by mutations in genes within the RAS/MAPK signaling pathway, thus called RASopathies. The RAS/MAPK pathway can also impact the signal transduction of hormones involved in body weight, carbohydrate, and lipid metabolism features scarcely studied only in animal models. This study aimed to describe me...